Exploring the Biden administration's use of Medicare to regulate drug pricing and the potential unintended consequences. Addressing Joe Biden's concerns about high drug prices in the US and the impact on drug innovation. Discussing negotiations between Medicare and drug companies and the significance of profit margins. Highlighting the high cost of healthcare in the US and proposing an alternative solution. Debating the use of the gazden flag in schools and concerns about potential censorship of political statements. Discussing the handling of a crisis in Florida and potential political impact. Sharing a funny moment about lack of political experience and discussing concerns about transgender issues.
Read more
AI Summary
AI Chapters
Episode notes
auto_awesome
Podcast summary created with Snipd AI
Quick takeaways
Medicare's price negotiation on drugs may lead to unintended consequences and decrease medical innovation and investment in the pharmaceutical industry.
Lowering drug prices without considering the financial investment required for drug development could discourage companies from investing in the development of new drugs, particularly for rare conditions.
Removing the profit margin through government action may diminish the incentive for pharmaceutical companies to invest in developing new drugs, leading to limited treatment options and a decrease in medical advancements.
Deep dives
The Biden administration's use of Medicare to price down on drug companies
The Biden administration is using Medicare to negotiate prices on drugs, claiming to help patients. However, this move could have unintended consequences. Medicare has named 10 drugs that will be subject to price negotiations, targeting widely used and costly medications for cancer, diabetes, and heart disease. While this may bring lower prices and savings for Medicare, it may also lead to a decrease in medical innovation and investment in the pharmaceutical industry. The reduction in profit margin may discourage companies from developing new drugs, particularly for rare conditions. An alternative solution could be to make other countries pay their fair share for American medication, but cramming down prices without considering the long-term effects could stifle innovation.
The importance of considering the financial cost of drug pricing policies
While politicians argue for lower drug prices by referencing how other countries pay less for American drugs, it is crucial to consider the financial investment required for drug development. Pharmaceutical companies spend billions on research and development, with estimates suggesting it costs between $1.3 to $2.4 billion to develop a single drug. The profit margin from successful drugs helps cover these high upfront costs and incentivizes further innovation. By cramming down prices, the government risks reducing the incentive for companies to invest in the development of new drugs. This could result in less investment in areas like rare diseases, where profit margins may already be lower. Ultimately, the unintended consequence of lower drug prices could be a decrease in medical innovation and limited treatment options for patients.
The flawed approach of removing the profit margin in drug pricing
The move to negotiate drug prices and remove the profit margin through government action may seem like a viable solution to high drug costs. However, it overlooks the importance of the profit margin in promoting innovation and investment in the pharmaceutical industry. When the profit incentive is diminished, there is less motivation for companies to invest significant resources in developing new drugs. This could have a detrimental impact on medical advancements, particularly in the treatment of rare diseases. Additionally, comparing drug prices between countries without considering the underlying dynamics of the healthcare systems and research investments can lead to misguided policies. Balancing the need for affordable medication with the importance of fostering innovation is crucial to ensure the development of life-saving drugs for patients.
Canadian father wins legal battle after misgendering his gender-confused daughter
A Canadian father, Robert Hoogland, has scored a legal win in the British Columbia Court of Appeal after being thrown in jail for misgendering his gender-confused teenage daughter. Hoogland took legal action after a children's hospital planned to administer testosterone to his daughter without his consent. The court dropped the jail sentence, but issued a fine of $30,000. Hoogland's case sets a precedent and highlights the struggle against the trans agenda in schools and the importance of parental consent.
Awards for men dressing as women: Dylan Mulvaney wins Streamy Award
Dylan Mulvaney, a man who dresses as a woman, won a Streamy Award and used his acceptance speech to call for support for trans people. Mulvaney, who is gay and claims to be a woman, garnered attention for his Days of Girlhood series on TikTok. Critics argue that Mulvaney's behavior remains unchanged, questioning the need to differentiate his gender identity. The reaction to such situations emphasizes the importance of defending women's rights and challenging the validity of men portraying women.
The Biden administration uses Medicare to cram down pricing on drug companies while claiming to help patients – but the law of unintended consequences is undefeated; the National Archives reveals there are 5,400 emails from Biden using pseudonyms; and Hurricane Idalia prepares to make landfall.
Click here to join the member exclusive portion of my show: https://utm.io/ueSEj
ExpressVPN - Get 3 Months FREE of ExpressVPN: https://expressvpn.com/ben
Balance of Nature - Start your journey to better health! For a limited time, get 40% off your first order as a preferred customer. Use promo code SHAPIRO at checkout: https://www.balanceofnature.com/
Legacybox - Shop Legacybox with my exclusive discount: https://www.legacybox.com/shapiro